Helios Clinical Research
G. Stephen DeCherney, MD, MPH has an extensive work experience in the academic and healthcare sectors. Since October 2009, they have been serving as a Professor of Medicine at the University of North Carolina at Chapel Hill. In addition to their academic role, they hold several positions in the biotech and investment fields. G Stephen is the Chair and Co-Founder of Helios Clinical Research since June 2021 and the Operating Partner at Grant Avenue Capital since February 2021. G Stephen has also served as an Executive Advisor at A1A Capital and e4-Services Inc, and as a Board Member at KnowBio Inc, KnowBio, Vast Therapeutics, and RFK Center for Human Rights and Justice. Furthermore, they have contributed to the University of Delaware Research Foundation as a member of the Board of Trustees since 2000.
G Stephen DeCherney, MD, MPH completed their primary education at Wilmington Friends School between 1959 and 1970. G Stephen then attended Columbia University from 1970 to 1974, earning a Bachelor of Arts degree in Molecular Biology. Following that, from 1974 to 1978, they attended Temple University - Lewis Katz School of Medicine where they obtained their Doctor of Medicine (MD) degree. Later, they pursued further education at Columbia University and from 1996 to 1998, they completed a Master of Public Health (MPH) degree with a focus on Healthcare Management.
This person is not in any offices
Helios Clinical Research
Helios partners with patients and physicians to optimize clinical research in over 20 site locations across the United States. Through direct engagement, Helios delivers high-quality data to biopharmaceutical partners. The research network at Helios is expansive and inclusive. The organization prioritizes patient education and care, and offersaccommodating settings for participation in integrated clinical research. By engaging with Helios, physicians can delegate the research process while they focus on patient treatment and data analysis for drug approval. As an active partner to biopharma, Helios is responsible for study startup, recruitment of patients, ongoing engagement with patients, and regulatory compliance factors. Through this active process, Helios accelerates the drug approval process.